Search

Displaying results 2221 - 2230 of 10000 in total
  1. Drug

    Butalbital

    go.drugbank.com/drugs/DB00241
    ApprovedIllicit

    Due to these risks, the use of butalbital-containing combination products is typically limited for use only in cases where other medications are deemed ineffective and such usage is advised to be carefully … Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group.

  2. Drug

    Eflornithine

    go.drugbank.com/drugs/DB06243
    ApprovedInvestigationalWithdrawn

    Eflornithine is an irreversible ornithine decarboxylase inhibitor originally developed as a treatment for human African trypanosomiasis. … a 68% reduction in the risk of death were observed.

  3. Drug

    Crinecerfont

    go.drugbank.com/drugs/DB18518
    ApprovedInvestigational

    [A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993] … [A264818] Crinecerfont is a selective antagonist of corticotropin-releasing factor (CRF) type 1 receptor that works to reduce excessive ACTH secretion from the pituitary.

  4. Drug

    Vigabatrin

    go.drugbank.com/drugs/DB01080
    ApprovedInvestigational

    Although administered as a racemic mixture, only the S(+) enantiomer is pharmacologically active. … [A202037] It was first introduced as an antiepileptic agent in the United Kingdom in 1989 and was used extensively until 1997, when an association with vision loss became apparent.

  5. Drug

    Nabiximols

    go.drugbank.com/drugs/DB14011
    Investigational

    isomer as [DB00470], or in a 1:1 formulation with CBD from purified plant extract as [DB14011]. … In Canada, Sativex® has received a Notice of Compliance (NOC) for use as an as adjunctive treatment for symptomatic relief of spasticity in patients with multiple sclerosis (MS) who have not responded

  6. Drug

    Sotagliflozin

    go.drugbank.com/drugs/DB12713
    ApprovedInvestigational

    Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind,[A244499] which is approved for use in the EU, in combination with insulin, to improve glycemic control in patients with type … 1 diabetes mellitus (T1DM) and a BMI ≥27 kg/m<sup>2</sup>.

  7. Drug

    Fluoxymesterone

    go.drugbank.com/drugs/DB01185
    ApprovedIllicit

    An anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women.

    International brands: U-Gono
  8. Drug

    Triazolam

    go.drugbank.com/drugs/DB00897
    ApprovedInvestigational

    Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances. … Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S.

  9. Drug

    Bretylium

    go.drugbank.com/drugs/DB01158
    Approved

    Bretylium blocks the release of noradrenaline from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular tachycardia and ventricular fibril...

  10. Drug

    Picosulfuric acid

    go.drugbank.com/drugs/DB09268
    ApprovedInvestigational

    Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery.

    Mixtures: AGAROL CON SABOR A FRAMBUESA